ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "psoriatic arthritis and statins"

  • Abstract Number: 2619 • 2018 ACR/ARHP Annual Meeting

    Effect of Statins on CRP Elevation in Patients with Psoriatic Arthritis

    Lesley Jackson1, Jeffry Bieber1,2 and R. Eric Heidel3, 1Graduate School of Medicine, Department of Internal Medicine, University of Tennessee Medical Center Knoxville, Knoxville, TN, 2UT Rheumatology, Knoxville, TN, 3Graduate School of Medicine, Division of Biostatistics, and Department of Surgery, University of Tennessee Medical Center Knoxville, Knoxville, TN

    Background/Purpose: It is well established that psoriatic arthritis is associated with increased cardiovascular disease risk. The use of statins may impart anti-inflammatory effects, possibly through…
  • Abstract Number: 910 • 2016 ACR/ARHP Annual Meeting

    Survival Benefit of Statin Use in Ankylosing Spondylitis and Psoriatic Arthritis: A General Population-Based Cohort Study

    Amar Oza1, Na Lu2 and Hyon K. Choi3, 1Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Boston, MA, 2Clinical Epidemiology, Boston University School of Medicine, Boston, MA, 3Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Recent studies have shown an increase in cardiovascular and all-cause mortality in ankylosing spondylitis (AS) and psoriatic arthritis (PsA).1 The hypothesized dual role of…
  • Abstract Number: 2063 • 2015 ACR/ARHP Annual Meeting

    The Survival Impact of Statins in Psoriasis and Psoriatic Arthritis: A General Population-Based Cohort Study

    Sian Yik Lim1, Na Lu2 and Hyon K. Choi2, 1Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 2Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Given their lipid-lowering and anti-inflammatory properties, statins may have dual cardioprotective and anti-rheumatic benefits in psoriasis or psoriatic arthritis. These effects may confer survival…
  • Abstract Number: 342 • 2013 ACR/ARHP Annual Meeting

    TNF Blockage In Psoriatic Arthritis: Long-Term Effect On Lipid Profile

    Julio C. B. Moraes1, Carla G.S. Saad1, Ana Cristina Ribeiro2, Claudia G Schainberg3, Celio R. Gonçalves2, Percival D Sampaio-Barros1 and Eloisa Bonfá2, 1Reumatologia, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 2Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

    Background/Purpose: Psoriatic arthritis (PsA) patients have increased cardiovascular morbidity and mortality. Altered lipid profile is an important risk factor for the development of these complications.…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology